Gregory J. Riely

94.6k citations

363 papers · 31.4k indexed · 25 hit papers · h-index 83

Impact in

Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 0.02%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 294
- Lung Cancer Treatments and Mutations 287
- Lung Cancer Diagnosis and Treatment 73
- Gastric Cancer Management and Outcomes 24
Oncology 227
- Lung Cancer Research Studies 107
- Colorectal Cancer Treatments and Studies 99
- HER2/EGFR in Cancer Research 26

Co-authors: Mark G. Kris Vincent A. Miller William Pao Marc Ladanyi Maureen F. Zakowski Maria E. Arcila Camelia S. Sima Helena A. Yu
Journals: Journal of Clinical Oncology (135 papers)Journal of Thoracic Oncology (49 papers)Clinical Cancer Research (37 papers)Annals of Oncology (18 papers)JCO Precision Oncology (13 papers)
Partner nations: United States South Korea Spain

In The Last Decade

Gregory J. Riely

343 papers receiving 30.9k citations

Hit Papers

15 papers align trajectories log scale

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer 2021 · 196 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 JAMA Oncology
2019 Annals of Oncology
2019 JAMA
2019 Journal of Clinical Oncology
2018 Journal of Clinical Oncology
2017 Journal of Clinical Oncology
2017 Cancer Discovery
2016 The Lancet Oncology
2016 The Lancet Oncology
2015 The Lancet Oncology
2015 Journal of Clinical Oncology
2014 The Lancet Oncology
2013 Clinical Cancer Research
2013 Clinical Cancer Research
2013 Journal of Clinical Oncology
2012 Clinical Cancer Research
2011 Modern Pathology
2011 Clinical Cancer Research
2011 Journal of Clinical Oncology
2010 Clinical Cancer Research
2009 Journal of Clinical Oncology
2006 Clinical Cancer Research
2006 Clinical Cancer Research
2005 PLoS Medicine
2005 PLoS Medicine

Peers

Countries citing papers authored by Gregory J. Riely

Since Specialization

Citations

This map shows the geographic impact of Gregory J. Riely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory J. Riely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory J. Riely more than expected).

Fields of papers citing papers by Gregory J. Riely

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory J. Riely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory J. Riely. The network helps show where Gregory J. Riely may publish in the future.

Co-authors

The 25 scholars most cited alongside Gregory J. Riely, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gregory J. Riely Line = papers co-authored together Gregory J. Riely links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	The impact of eligibility criteria on Kirsten rat sarcoma G12C inhibitor trials in patients with non–small cell lung cancer JNCI Journal of the National Cancer Institute ·Margaux Wooster, Michael May, Prashasti Agrawal, Jonathan Lee, Benjamin May, Xin Ma, Stephanie Bogdan, Catherine A. Shu, Brian S. Henick, Anjali Saqi, Mahesh Mansukhani, Gregory J. Riely, Dawn L. Hershman, Christine Garcia, Kathryn C. Arbour, Benjamin Herzberg	2025	0
2	Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors The Oncologist ·Christopher S. Nabel, Jeanne B. Ackman, Yin P. Hung, Abner Louissaint, Gregory J. Riely	2024	2
3	Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non–Small Cell Lung Cancer Trials Using Real-World Data Clinical Cancer Research ·Thanh G.N. Ton, Navdeep Pal, Huong Trinh, Sami Mahrus, Michael T. Bretscher, Robson Machado, Natalia Sadetsky, Nayan Chaudhary, Michael W. Lu, Gregory J. Riely	2022	13
4	Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions Clinical Cancer Research ·Noura J. Choudhury, Adam J. Schoenfeld, Jessica Flynn, Christina J. Falcon, Hira Rizvi, Charles M. Rudin, Mark G. Kris, Maria E. Arcila, Glenn Heller, Helena A. Yu, Marc Ladanyi, Gregory J. Riely	2021	47
5	Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach Clinical Cancer Research ·Jason C. Chang, Deepu Alex, Matthew J. Bott, Kay See Tan, Venkatraman Seshan, Andrew Golden, Jennifer L. Sauter, Darren J. Buonocore, Chad Vanderbilt, Sounak Gupta, Patrice Desmeules, Francis M. Bodd, Gregory J. Riely, Valerie W. Rusch, David R. Jones, Maria E. Arcila, William D. Travis, Marc Ladanyi, Natasha Rekhtman	2019	67
6	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance Clinical Cancer Research ·Helena A. Yu, Ken Suzawa, Emmet Jordan, Ahmet Zehir, Ai Ni, Hyunjae R. Kim, Mark G. Kris, Matthew D. Hellmann, Bob T. Li, Romel Somwar, David B. Solit, Michael F. Berger, Maria E. Arcila, Gregory J. Riely, Marc Ladanyi	2018	188
7	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS -Mutant Non–Small Cell Lung Cancer Clinical Cancer Research ·Kathryn C. Arbour, Emmett Jordan, Hyunjae R. Kim, Jordan Dienstag, Helena A. Yu, Francisco Sánchez-Vega, Piro Lito, Michael F. Berger, David B. Solit, Matthew D. Hellmann, Mark G. Kris, Charles M. Rudin, Ai Ni, Maria E. Arcila, Marc Ladanyi, Gregory J. Riely	2017	317
8	Antitumor Activity of RXDX-105 in Multiple Cancer Types with RET Rearrangements or Mutations Clinical Cancer Research ·Gang G. Li, Romel Somwar, James D. Joseph, Roger S. Smith, Takuo Hayashi, Leenus Martin, Aleksandra Franovic, Anni Schairer, Eric S. Martin, Gregory J. Riely, Jason Harris, Shunqi Yan, Wei Ge, Jennifer Oliver, Rupal Patel, Pratik S. Multani, Marc Ladanyi, Alexander Drilon	2016	49
9	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer Clinical Cancer Research ·Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian Druker, Thomas O’Hare, Marc Ladanyi, Monika A. Davare	2015	128
10	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations Cancer Discovery ·Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen, Leora Horn, Scott Gettinger, D. Ross Camidge, Gregory J. Riely, Bushi Wang, Yali Fu, Vikram K. Chand, Vincent A. Miller, William Pao	2014	295
11	Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker Clinical Cancer Research ·M. Catherine Pietanza, Kyuichi Kadota, Kety Huberman, Camelia S. Sima, John J. Fiore, Dyana K. Sumner, William D. Travis, Adriana Heguy, Michelle S. Ginsberg, Andrei I. Holodny, Timothy A. Chan, Naiyer A. Rizvi, Christopher G. Azzoli, Gregory J. Riely, Mark G. Kris, Lee M. Krug	2012	122
12	Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers Clinical Cancer Research ·Snjezana Doğan, Ronglai Shen, Daphne Ang, Melissa L. Johnson, Sandra P. D’Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Riely, Mark G. Kris, Maureen F. Zakowski, Marc Ladanyi Hit paper breakdown →	2012	493
13	Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes Journal of Clinical Oncology ·Geoffrey R. Oxnard, Binsheng Zhao, Camelia S. Sima, Michelle S. Ginsberg, Leonard P. James, Robert A. Lefkowitz, Pingzhen Guo, Mark G. Kris, Lawrence H. Schwartz, Gregory J. Riely	2011	118
14	Maintained Sensitivity to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Lung Cancer Recurring after Adjuvant Erlotinib or Gefitinib Clinical Cancer Research ·Geoffrey R. Oxnard, Yelena Y. Janjigian, Maria E. Arcila, Camelia S. Sima, Samantha L. Kass, Gregory J. Riely, William Pao, Mark G. Kris, Marc Ladanyi, Christopher G. Azzoli, Vincent A. Miller	2011	50
15	Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay Clinical Cancer Research ·Maria E. Arcila, Geoffrey R. Oxnard, Khédoudja Nafa, Gregory J. Riely, Stephen B. Solomon, Maureen F. Zakowski, Mark G. Kris, William Pao, Vincent A. Miller, Marc Ladanyi Hit paper breakdown →	2011	476
16	Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling Molecular Cancer Therapeutics ·Jamie E. Chaft, Maria E. Arcila, Paul K. Paik, Christopher Lau, Gregory J. Riely, M. Catherine Pietanza, Maureen F. Zakowski, Valerie W. Rusch, Camelia S. Sima, Marc Ladanyi, Mark G. Kris	2011	162
17	Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations Journal of Clinical Oncology ·Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely Hit paper breakdown →	2011	503
18	Analysis of Genetic Variants in Never-Smokers with Lung Cancer Facilitated by an Internet-Based Blood Collection Protocol: A Preliminary Report Clinical Cancer Research ·Nicolas Girard, Emil Lou, Christopher G. Azzoli, Rekha Reddy, Mark E. Robson, Megan Harlan, Irene Orlow, Yasushi Yatabe, Khédoudja Nafa, Marc Ladanyi, Agnès Viale, Mark G. Kris, Gregory J. Riely, Vincent A. Miller, Robert J. Klein, Keitaro Matsuo, William Pao	2010	70
19	Comprehensive Genomic Analysis Reveals Clinically Relevant Molecular Distinctions between Thymic Carcinomas and Thymomas Clinical Cancer Research ·Nicolas Girard, Ronglai Shen, Tianhua Guo, Maureen F. Zakowski, Adriana Heguy, Gregory J. Riely, James Huang, Christopher Lau, Alex Lash, Marc Ladanyi, Agnès Viale, Cristina R. Antonescu, William D. Travis, Valerie W. Rusch, Mark G. Kris, William Pao	2009	147
20	Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Clinical Cancer Research ·Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen F. Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris, Marc Ladanyi, Vincent A. Miller, William Pao Hit paper breakdown →	2006	664

About Gregory J. Riely

Gregory J. Riely is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Neurology and Pathology and Forensic Medicine, having authored 363 papers that have together received 31.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (287 papers), Lung Cancer Research Studies (107 papers), Colorectal Cancer Treatments and Studies (99 papers), Cancer Genomics and Diagnostics (75 papers), Lung Cancer Diagnosis and Treatment (73 papers), Cancer therapeutics and mechanisms (30 papers), HER2/EGFR in Cancer Research (26 papers) and Gastric Cancer Management and Outcomes (24 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (23.7k citations), Oncology (19.5k citations), Cancer Research (6.7k citations), Molecular Biology (11.0k citations) and Pathology and Forensic Medicine (2.2k citations). Gregory J. Riely has collaborated with scholars based in United States, South Korea and Spain. Frequent co-authors include Mark G. Kris, Vincent A. Miller, William Pao, Marc Ladanyi, Maureen F. Zakowski, Maria E. Arcila, Camelia S. Sima, Helena A. Yu, Kathryn C. Arbour and Harold Varmus. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Clinical Cancer Research, Annals of Oncology and JCO Precision Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact